



Topic treatment with NeoVIDERM cream to prevent and reduce skin toxicity in patients receiving radiotherapy for breast cancer

Trattamento topico con emulsione NeoVIDERM per prevenire e ridurre la tossicità cutanea in pazienti sottoposte a radioterapia complementare per neoplasia mammaria.

M.A. Mirri*, P. Soldini*, F. Pichinelli*, T. Palloni*, F. Fabretti* and A. Ciabattoni*

*UOC Radioterapia, A.C.O. S. Filippo Neri, Roma

Purpose

The most of people treated with external radiotherapy develop skin reactions sometimes with such intensity to induce a temporary suspension of the radiotherapy. Currently there are no standard therapeutic strategies for irradiated skin care and beneficial effects are observed after adequate hydration and use of steroid creams.

The objective of this study was to test the efficacy of prophylactic use of neoVIDERM cream (Betaglucan and Sodium Hyaluronate), a specific skin emulsion suited to treat light sunburns, skin irritations and inflammations. Reduction of grade ≥ 2 acute and late skin toxicity in patients irradiated for breast cancer was assessed. A secondary aim of the project was to evaluate quality of life of these patients and possible toxicity of the cream.

Materials and Methods

From April 2009 to June 2009 at the Radiotherapy Unit of San Filippo Neri Hospital in Rome, a total of 25 female patients treated with adjuvant radiotherapy for breast cancer, received prophylactic treatment with neoVIDERM skin emulsion.

Results

The rate of grade 2 dermatitis was 12 % (3 patients, two of them after the end of the treatment).
No patients needed to interrupt treatment.
No cream-induced toxicity.
Totally the compliance was very good (100% of the patients completed the supportive treatment).
At the one month follow up only one patient presented residual symptoms of radio induced dermatitis.



START

DURING-RT


ONE MONTH LATER



START

DURING-RT

ONE MONTH LATER



- **Adjuvant chemotherapy:**
23 out of 25 patients
- **Radiotherapy regimen:**
45 Gy/18 fr whole breast
10-15 Gy external or IORT boost

NeoVIDERM schedule:

- 3 times/day:
 - one week before
 - during RT
 - one month after RT.
- **Clinical evaluation and photos:**
 - at RT start
 - weekly during RT
 - 15 days after RT end
 - 30 days after RT end

Conclusions

NeoVIDERM skin emulsion use in conjunction with RT for breast cancer demonstrated to reduce incidence and severity (12% of grade ≤ 2) of skin acute toxicity during RT and moreover to encourage and speed up the regeneration and quick the healing of irradiated skin.

Our results suggest the possibility to use neoVIDERM skin emulsion to reduce the burden of radiation dermatitis. Further studies are needed to confirm these preliminary results.